Active Ingredient History
Dapagliflozin (trade name Farxiga in the U.S. and Forxiga in the EU and Russia) is a drug of the gliflozin class, developed by Bristol-Myers Squibb in partnership with AstraZeneca. Farxiga is a sodium-glucose cotransporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Combination drugs
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Kidney Injury (Early Phase 1)
Aging (Phase 1/Phase 2)
Alzheimer Disease (Phase 1/Phase 2)
Anemia (Phase 4)
Aortic Valve Disease (Phase 4)
Aortic Valve Stenosis (Phase 4)
Ascites (Phase 2)
Atrial Fibrillation (Phase 4)
Blood Glucose (Phase 4)
Blood Platelet Disorders (Phase 2/Phase 3)
Bone Diseases, Metabolic (Phase 4)
Breast Neoplasms (Phase 2)
Cardiac Catheterization (Early Phase 1)
Cardiomyopathies (Phase 2)
Cardiovascular Diseases (Phase 4)
Carotid Artery Diseases (Phase 4)
Catheter Ablation (Early Phase 1)
Cognition Disorders (Phase 3)
Coronary Artery Disease (Phase 4)
COVID-19 (Phase 3)
Cystinuria (Phase 2)
Diabetes Complications (Phase 4)
Diabetes Mellitus (Phase 4)
Diabetes Mellitus, Type 1 (Phase 4)
Diabetes Mellitus, Type 2 (Phase 4)
Diabetic Ketoacidosis (Phase 1)
Diabetic Nephropathies (Phase 4)
Diabetic Neuropathies (Phase 4)
Diet, Ketogenic (Phase 4)
Drugs, Investigational (Phase 1)
Endomyocardial Fibrosis (Phase 4)
Endothelial Cells (Phase 4)
Endothelium (Phase 4)
Exercise (Phase 2)
Fatty Liver (Phase 4)
Fibrosis (Phase 2)
Glomerulosclerosis, Focal Segmental (Phase 4)
Glucose Intolerance (Phase 4)
Glucose Metabolism Disorders (Phase 4)
Glucose Tolerance Test (Phase 3)
Glycemic Control (Phase 4)
Healthy Volunteers (Phase 2)
Heart Disease Risk Factors (Phase 2)
Heart Diseases (Phase 3)
Heart Failure (Phase 4)
Heart Failure, Diastolic (Phase 4)
Heart Failure, Systolic (Phase 4)
Hypercholesterolemia (Phase 4)
Hyperglycemia (Phase 4)
Hypertension (Phase 4)
Hypertrophy, Left Ventricular (Phase 4)
Hyperuricemia (Phase 2)
Hypoglycemia (Phase 4)
Hypotension (Phase 4)
Hypoxia (Phase 4)
Insulin (Phase 4)
Ketosis (Phase 4)
Kidney Diseases (Phase 4)
Kidney Failure, Chronic (Phase 2/Phase 3)
Kidney Function Tests (Phase 4)
Kidney Transplantation (Phase 4)
Lung Diseases (Early Phase 1)
Metabolic Syndrome (Phase 4)
Metabolism (Phase 4)
Mitochondrial Diseases (Phase 4)
Myocardial Infarction (Phase 4)
Myocardial Ischemia (Phase 4)
Myocardium (Phase 4)
Non-alcoholic Fatty Liver Disease (Phase 3)
Obesity (Phase 4)
Obesity, Morbid (Phase 2/Phase 3)
Pancreatic Neoplasms (Phase 1)
Percutaneous Coronary Intervention (Early Phase 1)
Polycystic Ovary Syndrome (Phase 3)
Prediabetic State (Phase 4)
Prehypertension (Phase 4)
Prostatic Neoplasms (Phase 1)
Proteinuria (Phase 4)
Renal Insufficiency, Chronic (Phase 4)
Risk Reduction Behavior (Phase 3)
Sleep Apnea Syndromes (Phase 2)
Sports Medicine (Early Phase 1)
Stroke (Phase 2)
Therapeutic Equivalency (Phase 1)
Thoracic Surgery (Phase 4)
Weight Loss (Phase 2)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
